Premas Biotech wins Gates Foundation grant to advance thermostable rabies vaccine

New Delhi: Premas Biotech has received a grant from the Gates Foundation to support early-stage development of its thermostable circRNA-VLP Rabies vaccine using the D-CRYPT™ Ver 3.0 platform.

The initiative specifically focuses on benefiting low- and middle-income countries (LMICs), where the need for affordable, durable, and easily deployable vaccines is greatest.

The circRNA platform represents a novel approach to vaccine development and is designed to improve both stability and effectiveness in global health settings where cold-chain storage can be a challenge. By leveraging this innovative approach, Premas aims to accelerate the creation of next-generation vaccines that can address critical unmet needs in LMICs.

Prabuddha Kundu, Co-Founder & Managing Director of Premas Biotech, commented: “This grant marks a significant milestone in advancing our circRNA-VLP vaccine platform. With the D-CRYPT™ Ver 3.0 technology, we are pushing the boundaries of what is possible in thermostable vaccine design. Our focus is to deliver innovative, next-generation solutions that address some of the most pressing global health challenges. At Premas, we remain deeply committed to redefining how vaccines are developed, stabilized, and deployed for maximum impact.”

Premas Biotech partners with biopharmaceutical companies globally to develop technologies from gene to IND development of therapeutic and vaccine candidates. The company specializes in infectious diseases, cancer, metabolic disorders, and inflammation. Its key platforms, D-Crypt™, Axtex-4D™, and C-Qwence™, are designed to address critical challenges in therapeutic development.